Beyond AREDS Formulations, What Is Next for Intermediate Age-Related Macular Degeneration (iAMD) Treatment? Potential Benefits of Antioxidant and Anti-inflammatory Apocarotenoids as Neuroprotectors

Age-related macular degeneration (AMD) is the commonest cause of severe visual loss and blindness in developed countries among individuals aged 60 and older. AMD slowly progresses from early AMD to intermediate AMD (iAMD) and ultimately late-stage AMD. Late AMD encompasses either neovascular AMD (nA...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oxid Med Cell Longev
Prif Awduron: Camelo, Serge, Latil, Mathilde, Veillet, Stanislas, Dilda, Pierre J., Lafont, René
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Hindawi 2020
Pynciau:
Review Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7803142/
https://ncbi.nlm.nih.gov/pubmed/33520083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/4984927
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg